期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CYP450s代谢酶基因表观遗传调控机制研究进展

原文传递
导出
摘要 生物转化是指外源性化学物在体内经酶促或非酶促反应转化为代谢产物的过程。生物转化过程包括Ⅰ相反应及Ⅱ相反应,其中Ⅰ相反应包括氧化、还原和水解反应。催化Ⅰ相反应的酶有95%为细胞色素P450酶系（cytochrome p450 enzyme system,CYP450s）。
作者 何志妮 张标 陈雯
机构地区 中山大学公共卫生学院
出处 《毒理学杂志》 CAS CSCD 北大核心 2014年第5期408-412,共5页 Journal of Toxicology
关键词 代谢酶CYP450s 表观遗传学 环境化学物暴露 基因表达调控
分类号 R114 [医药卫生—卫生毒理学]
  • 相关文献

参考文献30

  • 1Edward L, LeCluyse RPW, Melvin E, et al. Organotypic liver culture models: Meeting current challenges in toxicity testing[J]. Crit Rev Toxicol, 2012, 42(6) : 501-548.
  • 2Gomez-Lechon MJ, Donato MT, Castell JV, et al. Human hepatocytes as a tool for studying toxicity and drug metabolism[J]. Curr Drug Metab, 2003,4(4) :292-312.
  • 3Hussein AG, Pasha HF, E1-Shahat HM, et al. CYP1A1 gene polymorphisms and smoking status as modifier factors for lung cancer risk[ J]. Gene,2014,541 (1) :26-30.
  • 4Acevedo CA, Quinones LA, Catalan J, et al. Impact of CYP1A1, GSTM1, and GSTT1 polymorphisms in overall and specific prostate cancer survival [ J ]. Urol Oncol, 2014,32 ( 3 ) :280-290.
  • 5XueH, Lu Y, Xue Z, et al. The effect of CYP1A1 and CYP1A2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis [J]. Tumour Biol, 2014, 35(5):4741-4756.
  • 6Yan F, Xu JF, Liu XF, et al. Interaction between smoking and CYP2C19 * 3 polymorphism increased risk of lung cancer in a Chinese population[ J]. Tumour Biol, 2014. 35 (6) :5295-5298.
  • 7李韶南,刘震,罗义,陈平安,雷晓明,李广镰.细胞色素P4502C19基因多态性与急性冠状动脉综合征患者氯吡格雷抵抗及预后关系[J].中华内科杂志,2013,52(11):961-965. 被引量：18
  • 8Cortessis VK, Thomas DC, Levine A J, et al. Environmental epigenetics : prospects for studying epigenetic mediation of exposure-response relationships Hum Genet, 2012,131(10) :1565-1589.
  • 9Zanger UM, Turpeinen M, Klein K, et al. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation [ J ]. Anal Bioanal Chem, 2008,392 (6) : 1093-1108.
  • 10Taby R, Issa JP. Cancer epigenetics [ J]. CA Cancer J Clin, 2010,60(6) :376-392.

二级参考文献14

  • 1张永珍,高炜.氯吡格雷抵抗的机制与对策[J].中华内科杂志,2006,45(3):250-252. 被引量：12
  • 2柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量：2125
  • 3Bouman H J,Sch(o)mig E,van Werkum JW,et al.Paraoxonase-1 is a major determinant of clopidogrel efficacy.Nat Med,2011,17:110-116.
  • 4Varenhorst C,James S,Erlinge D,et al.Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.Eur Heart J,2009,30:1744-1752.
  • 5Müller I,Besta F,Schulz C,et al.Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement.Thromb Haemost,2003,89:783-787.
  • 6Mega JL,Close SL,Wiviott SD,et al.Cytochrome p-450 polymorphisms and response to clopidogrel.N Engl J Med,2009,360:354-362.
  • 7Frere C,Cuisset T,Morange PE,et al.Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.Am J Cardiol,2008,101:1088-1093.
  • 8Mega JL,Hochholzer W,Frelinger AL,et al.Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.JAMA,2011,306:2221-2228.
  • 9Lev EI,Patel RT,Maresh KJ,et al.Genetic determinants of response to clopidogrel and cardiovascular events.N Engl J Med,2009,360:363-375.
  • 10Guthikonda S,Granada J,DeLao T,et al.Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention:the role of dual drug resistance.J Am Coll Cardiol,2006,47:27-33.

共引文献17

毒理学杂志
2014年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部